

1 **Directed Evolution of Replication-Competent dsDNA Bacteriophage towards New Host**  
2 **Specificity**

3

4 **Jing Liang<sup>1</sup>, Huibin Zhang<sup>2</sup>, Yee Ling Tan<sup>1</sup>, Huimin Zhao<sup>3,\*</sup>, and Ee Lui Ang<sup>1,\*</sup>**

5

6 <sup>1</sup> Strain Engineering, Singapore Institute of Food and Biotechnology Innovation, Singapore  
7 138669, Singapore.

8 <sup>2</sup> Metabolic Engineering Research Laboratory (MERL), Agency for Science, Technology, and  
9 Research (A\*STAR), Singapore, 138669, Singapore.

10 <sup>3</sup> Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-  
11 Champaign, Urbana, IL 61801, United States.

12 \*To whom correspondence should be addressed. H.Z. (email: zhao5@illinois.edu) and E.L.A.  
13 (email: ang\_ee\_lui@sifbi.a-star.edu.sg)

14

15 **ABSTRACT**

16 In the fight against antimicrobial resistance, bacteriophage is a promising alternative to  
17 antibiotics. However, due to their narrow spectrum, phage therapy requires the careful  
18 matching between host and bacteriophage to be effective. Despite our best efforts, nature  
19 remains as the only source of novel phage specificity. Directed evolution can potentially open  
20 an avenue for engineering phage specificity and improving qualities of phages that are not  
21 strongly selected for in their natural environments but are important for therapeutic applications.  
22 In this work, we present a strategy that generates large libraries of replication-competent phage  
23 variants directly from synthetic DNA fragments, with no restriction on their host specificity.  
24 Using the T7 bacteriophage as a proof-of-concept, we created a large library of tail fiber  
25 mutants with at least  $10^7$  unique variants. From this library, we identified mutants that has  
26 broadened specificity as evidenced by their novel lytic activity against *Yersinia enterocolitica*,  
27 a strain that the wild-type T7 was unable to lyse. Using the same concept, mutants with  
28 improved lytic efficiency and characteristics, such as lytic condition tolerance and resistance  
29 suppression, were also identified. However, the observed limitations in altering host specificity  
30 by tail fiber mutagenesis suggests that other bottlenecks could be of equal or even greater  
31 importance.

32

33 **KEYWORDS**

- 34 Phage engineering, directed evolution, phage specificity, synthetic phage platform, tail fiber
- 35 engineering

## 36 INTRODUCTION

37 With the growing threat of antimicrobial resistance (AMR) and the lack of adequate drugs in  
38 the pipeline, AMR infection is poised to overtake cancer as the leading cause of death by 2050,  
39 resulting in the loss of 10 million lives and US\$8 trillion in GDP annually <sup>1,2</sup>. Phage therapy  
40 has been identified as one of the most promising alternatives currently on the horizon, and  
41 recent successes have prompted renewed interest in harnessing the potential of this century-old  
42 practice <sup>3-6</sup>.

43

44 One of the key limitations in phage therapy has been the host-specificity of phages. Being  
45 highly host-specific, phages tend to be narrow-spectrum, and require careful matching to the  
46 specific infection <sup>6</sup>. Current treatment strategy often relies on the screening of a large library  
47 of characterized phage isolates in multiple phage banks to find ones that work for the specific  
48 infection <sup>5,7,8</sup>. This requirement makes phage therapy resource-intensive and expensive.  
49 Furthermore, being overly specific also allows the host to readily evolve resistance towards  
50 any given phage, which invariably occurs <sup>9</sup>. If resistance occurs before therapeutic effect is  
51 achieved, a re-screening for new phages may become necessary. Furthermore, as phages rely  
52 on their hosts for replication, highly effective phages that are too effective in killing their hosts  
53 would have gone extinct in nature. However, highly effective phage is exactly what we desire  
54 in phage therapy.

55

56 In an attempt to address this limitation, various groups have developed strategies to artificially  
57 adapt phages to new hosts <sup>10,11</sup>. However, these strategies require the availability of a phage  
58 that can invade the target strain – i.e. we need to know the solution to the problem before we  
59 can solve it. In addition, because they are natural isolates, we cannot expect the resultant phages  
60 to be 100% efficient. More recently, Dunne et al. and Yehl et al. reported the use of targeted  
61 and random mutagenesis to expand the host range of tailed phages <sup>12,13</sup>. However, because Yehl  
62 et al. relied on the native host for library preparation, it requires that the resultant library,  
63 however diverse, must retain their specificity towards the native host. Variants that resulted in  
64 a complete switch in specificity will be lost. While Dunne et al. circumvented the problem  
65 through direct genome transfection, the transformation efficiency would limit the library size  
66 for many hard-to-transform wild-type strains.

67

68 In this work, we aim to unleash the full power of directed evolution to supercharge the  
69 capabilities of these host adaptation systems and to enable large phage library preparation

70 without the need to maintain native host compatibility<sup>14-16</sup>. To enable the rapid engineering  
71 and evolution of replication-competent phages with new host specificity, we designed a  
72 versatile Golden Gate-based assembly platform to synthesize the phage genomes from  
73 synthetic DNA fragments. These synthetic phage genomes can have features that allow for the  
74 rapid high efficiency swap-in of mutagenized fragments, and the resultant genomic libraries  
75 can be rebooted by cell-free transcription and translation (TXTL), thereby eliminating the need  
76 for the library variants to infect the native host.

77

78 Using this platform and T7 phage as a model, we generated large random mutagenesis libraries  
79 targeting 3 tail component proteins – minor tail protein gp11, major tail protein gp12, and tail  
80 fiber gp17 – with 5-8 nt changes per gene, and screened the variant libraries against new strains  
81 and species that are resistant to wild-type T7 phage. The tail components are needed for host  
82 attachment and are thought to be important determinant of host specificity. We further showed  
83 that directed evolution can be used to improve the lysis as well as anti-resistance performance  
84 of phages.

85

## 86 **RESULTS**

### 87 *Recoding and chemical synthesis of phage T7Syn*

88 To enable Golden Gate assembly, we recoded the T7 phage by removing all *BsaI* and *Esp3I*  
89 sites within protein coding sequences by making synonymous codon substitutions. Sites that  
90 are in regulatory regions were removed by making a single A to G substitution. In total, 46  
91 substitutions and a single 13-bp insertion were made. The new genome was then chemically  
92 synthesized by a commercial vendor in 14 fragments and cloned into plasmids. Fragments that  
93 were toxic to *E. coli* were propagated in yeast plasmids. A list of fragments used for the  
94 assembly can be found in Table S8. Similar effect can be achieved via a 52-fragment assembly  
95 as demonstrated by Pryor et al.<sup>17</sup>. After sequencing confirmation, the fragments were amplified  
96 by PCR and assembled, using a single-step Golden Gate (GG) reaction, into a complete phage  
97 genome. The genome was then rebooted via a cell-free transcription translation (TXTL)  
98 reaction, and plated onto an *E. coli* BL21 bacterial lawn for plaque formation and isolation  
99 (Figure 1A). More than 10<sup>4</sup> plaque forming units (pfu) were obtained from a 12 μL TXTL  
100 reaction.

101

102 To confirm that the plaques were from the recoded phages, we PCR amplified a heavily  
103 recoded fragment from 8 different randomly selected plaques, and digested it using *BsaI*. All

104 8 amplicons could not be digested by *BsaI*, whereas the amplicons from the wild-type T7 phage  
105 (T7wt) showed clear signs of digestion (Figure 1B). This shows that the complete T7 genome  
106 could be assembled and rebooted at high efficiency.

107

108 We performed extensive comparison between the synthetic T7 phage named T7Syn and the  
109 wild-type T7 phage to ensure that our recoding did not affect the host range and the propagation  
110 of the phage. Using a liquid lysis assay on 47 different strains, we found that T7Syn has the  
111 same host range as T7wt (Figure 1E). The burst time (Figure 1D) and resultant final titer  
112 (Figure 1C) of T7Syn were found to be identical to that of T7wt. The complete T7Syn genomic  
113 sequence as confirmed by next generation sequencing (NGS) is available at GenBank  
114 MW248381.

115

#### 116 *Reassembly and functionalization of T7Syn*

117 T7Syn was then used as the template to generate a diversity of variants. Insertion, deletion, re-  
118 arrangement, substitution, and mutagenesis, can all be accomplished easily by PCR using the  
119 appropriate primers, followed by Golden Gate assembly and TXTL rebooting. The resultant  
120 pfu is inversely related to the number of fragments in the reassembly. From one 12  $\mu$ L TXTL  
121 reaction, we could obtain around  $10^5$  pfu for a 6-fragment assembly, and up to  $10^7$  pfu for a 3-  
122 fragment assembly, when titered on *E. coli* BL21.

123

124 To prepare for the mutagenesis of gp11, gp12, and gp17, we reintroduced *BsaI* sites flanking  
125 those genes – gp11 and gp12 as one cassette, and gp17 as another cassette. The restriction sites  
126 were reintroduced by PCR, and the variants were assembled using Golden Gate assembly. As  
127 the N-terminal end of gp17 is involved in the phage assembly, we targeted only the C-terminal  
128 end (175-553) for mutagenesis. Three variants were made: (1) T7Syn-1112Bs has *BsaI* site  
129 inserted before Gp11 and after Gp12, (2) T7Syn-17Bs has *BsaI* site introduced at amino acid  
130 position 175 of Gp17 by synonymous base substitution, and has *BsaI* site inserted in the  
131 intergenic region after Gp17 (Figure 2A), (3) T7Syn-111217Bs is a combination of the first  
132 two variants that allows double substitution (GenBank MW248382). After plaque isolation,  
133 the genomic DNA of the phage variants was extracted from high titer lysates. Restriction  
134 digestion of the genomic DNA by *BsaI* confirmed that *BsaI* sites have been successfully  
135 introduced at the expected sites (Figure 2B). The purified genomic DNA was then used as the  
136 ‘backbone’ for subsequent Golden Gate reactions to swap in engineered or mutagenized tail  
137 components. Some *BsaI* modifications affected phage propagation as evident in a delayed burst

138 time (Figure 2C). However, for most cases, the effect would not impact their application since  
139 swapping in a component by Golden Gate (GG) reactions removes the *BsaI* modifications. If  
140 avoiding such handicap is important, special care needs to be taken for modifications that are  
141 within intergenic regions, where many regulatory regions reside.

142

#### 143 *Generation of large high diversity libraries*

144 Because of the potential amplification that could occur during the TXTL reaction, we needed  
145 to ascertain that the observed pfu after TXTL was a true representation of library size. We  
146 designed an experiment to measure the library size of our reaction by tag sequencing. First,  
147 *BsaI* sites flanking gp17 were introduced together with a 19bp insertion at the 3' end to simulate  
148 the effect of a barcode tag (Figure 2A). As the insertion was within the intergenic region of a  
149 polycistronic operon, the insertion led to the disruption of the following gene, which affected  
150 the propagation of the resultant phage. Our first attempt resulted in a phage that had a slower  
151 replication cycle than wild type phages (Figure 2C, T7Syn-17TagBs). Since we needed to  
152 minimize the effect of the tag on phage propagation so as to reduce the amount of bias, we  
153 padded the insertion with longer T7Syn sequences, which fully reversed the burst time delay  
154 (T7Syn-17Tag2Bs). More detailed description of the modifications made in T7Syn-17Tag2Bs  
155 can be found in Figure S2.

156

157 Using the extracted genomic DNA as backbone, we swapped in a copy of the T7Syn Gp17 that  
158 has been tagged with a 19bp barcode capable of distinguishing up to  $10^9$  unique variants  
159 (T7Syn-17Tagged). An analysis of GG efficiency showed that around 30% of the input DNA  
160 had been converted into completed product (Figure S3). Following TXTL,  $10^7$  pfus were  
161 obtained from the reaction. We pooled all the plaques and sequenced the barcodes by NGS.  
162 The result indicates that there were  $10^7$  unique variants in our pooled sample, suggesting that  
163 under our reaction condition, the pfu obtained after TXTL is a true representation of library  
164 diversity.

165

#### 166 *Evolving host specificity by tail fiber mutagenesis*

167 It has been reported in previous works that grafting a T3 phage tail fiber onto T7 will confer  
168 the latter with the host range of T3 phage<sup>10,11</sup>. T3 phage can form plaques only on *Escherichia*  
169 *coli* B strains whereas T7 phage can form plaques on both *E. coli* B and K12 strains. As a  
170 proof-of-concept, we wanted to see if we can evolve the T3 tail fiber of a T7/T3 hybrid phage  
171 to regain the ability to form plaques on *E. coli* K12 strains.

172

173 Using T7Syn-17Bs as the backbone, we swapped in the T3 tail fiber from amino acid position  
174 176 up to its stop codon. In agreement with previous studies, we found that the resulting T7Syn-  
175 17T3 hybrid can indeed achieve a complete specificity switch, achieving an efficiency of  
176 plating (EOP) of  $<10^{-7}$  on *E. coli* MG1655, a K12 strain compared to *E. coli* BL21, a B strain  
177 (Figure 3A). We then reintroduced *BsaI* sites to T7Syn-17T3 and swapped in a library of  
178 randomly mutagenized 17T3 tail fiber variants each with 5-8 random nucleotide substitutions.  
179 The mutagenized phage was rebooted by TXTL, resulting in a titer of around  $10^6$  pfu/12  $\mu$ L  
180 TXTL on BL21. For mutagenized libraries, pfu measurements will always underestimate the  
181 true titer of the reaction, because mutants that have lost the ability to invade BL21 will not  
182 show up in the pfu count. We plated dilutions of the TXTL reaction onto a lawn of MG1655 at  
183 a density where individual plaques could be picked. Mutants that could form large clear plaques  
184 on MG1655 could be obtained readily. We estimate that the rate of positive gain-of-function  
185 mutations was close to 1%. Sequencing of the positive mutants revealed that these mutants  
186 have between 3 to 5 amino acid changes within Gp17, and have unchanged Gp11 and Gp12.  
187 Our small sampling of 4 positive mutant sequences did not reveal any consensus mutations.  
188 The observed mutation rate was within the expected range of our mutagenesis library.

189

190 The gain-of-function phenotype was so easily obtainable that we could pick up some positive  
191 mutants from the negative control, where we swapped in an unmutated 17T3 tail fiber (Figure  
192 3B). Sequencing of these positive mutants from the negative control revealed that these mutants  
193 have only one amino acid change within either Gp17 or Gp12, and are most likely the result of  
194 PCR error or replication error. This shows that T3 to T7 host range switch requires only a single  
195 nucleotide change. In this instance, T3 to T7 host range extension was found to only require  
196 small evolutionary steps. To challenge the platform, we next tested its ability to bridge bigger  
197 evolutionary gaps.

198

### 199 *Testing the limits of directed evolution*

200 To select potential targets, we tested a panel of 47 strains for their susceptibility towards wild-  
201 type T7 phage, and eliminated those that were found to be fully susceptible in a liquid lysis  
202 assay (Figure 1E, Figure S4). Twenty non-susceptible strains were selected for further testing  
203 using a plate-based titer assay where serially diluted T7 phages were dotted onto a lawn of  
204 bacteria. Three strains showed zones of inhibition at high T7 concentrations above  $10^7$  pfu/mL  
205 – *Salmonella enterica* ATCC#29630, *Salmonella enterica* ATCC#51741, and *Yersinia*

206 *enterocolitica* (YE) ATCC#23715 (Figure 3C, Supplemental Figure S5). Other than these 3  
207 strains that appeared to be mildly susceptible, we selected based on their clinical significance,  
208 another 9 non-susceptible strains including enterohemorrhagic *E. coli*, *Acinetobacter*  
209 *baumannii*, *Pseudomonas putida*, *Citrobacter braakii*, *Citrobacter freundii*, *Shigella sonnei*,  
210 and *Shigella flexneri*. All in all, 12 strains were selected for the screening of our T7 gp17  
211 mutagenesis library (Figure S6).

212  
213 Random mutagenesis libraries (5-8 nt changes per gene) of Gp17, Gp11-12, and Gp11-  
214 12/Gp17 double mutant were generated from T7Syn-17Bs, T7Syn-1112Bs, and T7Syn-  
215 111217Bs at an estimated Golden Gate efficiency of 30%, 30%, and 9% respectively. After  
216 TXTL reboot, the resultant titer on BL21 was  $10^6$ ,  $10^6$ , and  $10^2$  per 12  $\mu$ L reaction. The reaction  
217 efficiency for double mutant was proximately the product of the single mutant reaction  
218 efficiencies. Given the low Golden Gate efficiency and the large sequence space, we believe  
219 that creating a large enough double mutant library is extremely challenging. Double mutant  
220 libraries were therefore excluded from the subsequent experiments.

221  
222 We plated at least  $5 \times 10^5$  pfu of Gp17 mutants and at least  $5 \times 10^3$  Gp11-12 mutants separately  
223 onto lawns of the 12 strains we identified for screening. The Gp17 mutant library formed  
224 hundreds of small plaques on YE, while plating a similar number of T7wt phage or T7Syn  
225 phage did not result in any plaque (Figure 3D). Eight plaques were picked from the initial YE  
226 plate, resuspended in 200  $\mu$ L phosphate buffered saline to make plaque stocks, which were  
227 then titered on a fresh lawn of YE, *E. coli* K-12 (MG1655), and *Yersinia pseudotuberculosis*  
228 IP2666. The plaque stocks of 8 different plaque isolates showed variable levels of plaque-  
229 forming activity towards YE, while they all showed consistent plaque-forming activity towards  
230 K12 and IP2666 (Figure 3E, only 4 shown). The plaque stock titers on K12 and IP2666 were  
231 around  $10^8$  pfu/mL, and the titers on YE were around 100-fold less. To ensure homogeneity,  
232 mutants that showed clear plaque-forming activity were re-isolated twice by plating at low  
233 density ( $\sim 100$  pfu/plate) and plaque picking. The best mutant based on titer and plaque  
234 appearance, T7Syn-17m5, contains 4 amino acid changes in Gp17. T7Syn-17m5 forms small  
235 (1-2 mm) clear plaques on BL21, MG1655, and YE, and is capable of liquid lysis (Figure 3F).  
236 The mutant libraries did not form plaques on the other strains we screened (Figure S6). Our  
237 results indicate that the strains that can be targeted by mutagenesis is limited to closely related  
238 species.

239



240 *Improving Yersinia lysis efficiency through directed evolution*

241 While evolving new specificity turned out to be extremely challenging, we hypothesized that  
242 improving a weak phage should be a more amenable problem. For this, we tried to improve the  
243 lytic activity of phages through mutagenesis of the tail components. We started with T7Syn-  
244 17m5 phage that we had picked up from the earlier screen, and we wanted to see if we could  
245 further improve its activity towards YE through a second round of mutagenesis.

246

247 Preparation of the mutagenesis libraries was performed in a manner similar to previous  
248 examples – we reintroduced *BsaI* sites flanking the region of interest, then we swapped in a  
249 mutagenized copy into the phage genomic DNA through Golden Gate reaction. We created  
250 two libraries for each of the two phages, one for Gp11-12 and another for Gp17. The rebooted  
251 phage libraries were plated onto a lawn of target bacteria, and we picked the 8 biggest and  
252 clearest plaques for further characterization.

253

254 For T7Syn-17m5, second-round mutagenesis of Gp17 did not result in any significant  
255 improvement on its YE lysis performance, based on both plaque titer and liquid lysis assay.  
256 However, one of the selected second-round Gp17 mutants, T7Syn-5m7 showed decreased lysis  
257 performance towards BL21 while maintaining similar lysis performance against YE (Figure  
258 3F and G). The decoupling of the activity towards YE and BL21 suggests that it might be  
259 possible to shift specificity away from BL21 to eventually achieve a host range switch instead  
260 of host range broadening. Although further mutagenesis of Gp17 did not result in significant  
261 improvement on YE lysis, mutagenesis of Gp11-12 did improve YE lysis. Using T7-Syn17m5  
262 as the parent, mutagenesis of Gp11-12 resulted in a variant, T7Syn-12m1, that showed faster  
263 lysis time than T7Syn-17m5 (Figure 3F). Sequencing analysis showed that T7Syn-12m1 has a  
264 single amino acid change within Gp12 (Figure S1).

265

266 Interestingly, T7Syn-17m5 and T7Syn-5m7 both showed resistance suppression in BL21  
267 (Figure 3H). After prolonged incubation with phages, BL21 started to develop resistance  
268 towards T7wt and T7Syn, and a resistant culture regrew after 8 hours. T7Syn-17m5 and T7Syn-  
269 5m7 were able to suppress the rise of resistance for at least 12 hours.

270

271 *Improving Klebsiella lysis efficiency through directed evolution*

272 To test the generalizability of this directed evolution strategy, we tried to improve the lysis  
273 performance of a K11 bacteriophage tail fiber towards *Klebsiella sp. 390* (K390). K11 Gp11,

274 12, 17 homologues were amplified in fragments to remove *BsaI* and *Esp3I* restriction sites,  
275 pre-assembled in two plasmids by Golden Gate assembly, and sequence verified. These  
276 recoded tail components were then used to replace their T7 homologues to create two versions  
277 of T7-K11 hybrid phage. T7Syn-K111217 contain a complete swap of Gp11, Gp12, and Gp17,  
278 whereas T7Syn-TK17 contain a partial swap of gp17 from amino acid position 169 up to its  
279 stop codon, as well as a mutagenized copy of T7Gp11-12 (Figure 4A).

280

281 In agreement with previous observations, T7Syn-K111217 could form plaques on K390<sup>10,11</sup>.  
282 In addition, we also found that T7Syn-TK17 could form plaques on K390 too (Figure 4B). This  
283 showed that K11Gp11-12 were not necessary for T7 phage to acquire the ability to lyse K390.  
284 Slight modification of T7Gp11-12 was sufficient to complement the TK17 hybrid tail fiber to  
285 enable K390 lysis. Intriguingly, we observed that both T7Syn-K111217 and T7Syn-TK17's  
286 activity towards K390 were highly media-dependent. Both phages were able to lyse K390  
287 grown in nutrient broth (NB) efficiently, but fail to lyse K390 grown in lysogeny broth (LB)  
288 (Figure 4C and D). We wanted to see if we could improve its activity towards K390 in LB  
289 through mutagenesis.

290

291 Mutagenesis was carried out on K11Gp11-12, K11Gp17 as described in the previous section.  
292 The mutagenized phage libraries were screened on K390 grown in LB and the 8 biggest and  
293 clearest plaques were picked for further analysis. From these plaques, we isolated mutants that  
294 showed markedly improved lysis performance on K390 grown in LB. The best mutant, T7Syn-  
295 KmL2, could effect liquid lysis in a K390 LB culture, whereas T7Syn-K111217 and T7Syn-  
296 TK17 could not (Figure 4C and D). On plaque forming assay, T7Syn-17KmL2 formed clear  
297 plaques while the parents formed hazy plaques. Sequencing revealed that the improved  
298 phenotype is conferred by a single amino acid change in K11 Gp17 within the T7Syn-K111217  
299 variant. Unfortunately, plating the T7-K11 hybrid mutagenesis libraries on other *Klebsiella*  
300 strains that are resistant to K11 phage, such as *Klebsiella oxytoca* and *Klebsiella pneumoniae*,  
301 did not result in any plaque formation.

302

303

## 304 **DISCUSSION**

305 In this study, we have demonstrated the speed and flexibility of our phage engineering platform  
306 using T7 phage. However, this strategy should be applicable to many other dsDNA phages.  
307 Since no attachment, invasion, and lysis is necessary for phage assembly in cell-free

308 transcription translation (TXTL), the engineered phages do not need to retain their activity  
309 towards *E. coli* or any particular host. The only requirement for this platform is that the  
310 transcription and translation machineries must be compatible to that of *E. coli*. This limitation  
311 can most likely be overcome through the development of TXTL reactions that are based on the  
312 lysate from the species of interest.

313

314 As phage and their host have coevolved over millions of years, they have become incredibly  
315 diverse. As a result, the evolutionary distance between far away lineages is way beyond the  
316 reach of random mutagenesis<sup>18</sup>. For example, the K11 tail fiber is almost twice as big as that  
317 of T7, and it contains a catalytic domain that can digest bacterial capsule<sup>19,20</sup>. It is extremely  
318 unlikely that such functionality can be obtained through random mutagenesis, thereby limiting  
319 the targetable strains to only closely related species. There is a sweet spot for new host  
320 adaptation – being too close would make the host susceptible to the parent phage, being too far  
321 would make the host unreachable by one-step evolution. For example, *Yersinia pestis* is very  
322 closely related to *E. coli* K-12,<sup>21</sup> and we found that *Y. pseudotuberculosis* IP2666, a strain  
323 most closely related to *Y. pestis*, is fully susceptible to T7 phage<sup>22</sup>. We were not able to test  
324 *Yersinia pestis* due to regulatory limitations. *Yersinia enterocolitica* is slightly further from *Y.*  
325 *pestis*, and is highly resistant towards T7 phage. *Y. enterocolitica* turned out to be within the  
326 sweet spot, and we could evolve the parent phage to overcome the resistance. Given the  
327 limitations on the bridgeable evolutionary distance, we expect the main application of directed  
328 evolution will be to target closely related strains, such as the resistant strains that have been  
329 derived from a susceptible parent strain.

330

331 One key limitation of our study, that we have realized only during peer review, is that the tail  
332 fibers and the packaged genome became unlinked during TXTL, which has made the direct  
333 screening from TXTL ineffective. While direct screening could be used for the mutagenesis of  
334 components, such as the kinases, nucleases and polymerases, that are expressed after host entry,  
335 direct screening of structural components should have been avoided. The linkage between  
336 structural components and the packaged genome could be restored either by performing TXTL  
337 under microencapsulation<sup>23,24</sup>, or by allowing one round of lysis in the native host. Given the  
338 limitation, we can only expect our screen to work on strains that are mildly susceptible to the  
339 wild-type phage. It is not a good gauge of the evolutionary distance bridgeable by random  
340 mutagenesis. We will address this limitation in a follow-up study.

341

342 Another limitation is that plaque appearance screening is most effective for detecting mutants  
343 that have improved from non-plaque forming to plaque forming. When the parent phage is non-  
344 plaque forming, we can plate  $10^6$  mutant phages on one plate and will still be able to pick up  
345 the few that are able to form plaques. However, when the parent is plaque forming, we can  
346 only fit  $10^3$  mutant phages on one plate before the plaque density becomes too high to detect  
347 the few clearer or bigger plaques. As a result, further rounds of mutagenesis are unlikely to  
348 result in marked improvement once the phage becomes plaque forming.

349

350 Recently, Yehl et al. reported the use of tail fiber mutagenesis to expand the host range of tailed  
351 phages<sup>13</sup>. They proposed that there are variable loop regions on the tail fiber that are important  
352 for host specificity. Focusing the mutagenesis on these smaller regions can potentially make  
353 our screening more effective. However, it is worth noting that for T7Syn-17m5 that has  
354 acquired the ability to attack YE, all 4 amino acid changes reside outside the variable loop  
355 regions. We also found that while Gp17 is important for acquiring new targeting specificity,  
356 Gp11-12 is important for making the process efficient. Because Yehl et al. relied on  
357 recombination within a susceptible host to generate the phage library, it requires that the  
358 resultant library, however diverse, must retain their specificity towards the native host. Variants  
359 that resulted in a complete switch in specificity will be lost. We believe that our library  
360 preparation method, when done with microencapsulated TXTL, will complement the findings  
361 by Yehl et al., and allows for the generation of large phagebody libraries without the backward  
362 compatibility requirement.

363

364 Lastly, when it comes to engineering lytic growth in new hosts, it is important to look beyond  
365 the tail components. As Yosef et al. have pointed out in their study, phages can deliver DNA  
366 to many more hosts than they can replicate in<sup>11</sup>. This suggests that other means of phage  
367 resistance might be more important than phage attachment<sup>25</sup>. Engineering the host inhibition  
368 and host lysis components may enable lytic growth in many more hosts than engineering tail  
369 components alone. However, a method to quickly identify the bottleneck in the lytic growth  
370 cycle needs to be developed.

371

372 In summary, by directly assembling the full phage genome from PCR fragments, we have  
373 circumvented many limitations associated with yeast and cell-based assembly systems. This  
374 platform allows for the extensive re-engineering of dsDNA phage and for the creation of high  
375 diversity mutagenesis libraries. With a large library of recoded phages, it will be possible to

376 curate a collection of modular compatible phage parts, where we can have ready-to-use host  
377 inhibition module, DNA replication module, packaging module, host invasion module, and  
378 host lysis module. This platform should help propel phage engineering into the synthetic  
379 biology era, where we can pick and choose functionality modularly to target specific organisms.  
380 In the near future, we can look forward to the emergence of highly effective therapeutic phages  
381 that are evolved in the lab, and may even have properties that preclude its existence in nature.

382

383

## 384 **METHODS**

### 385 *Assembly of chemically synthesized genome*

386 The entire T7 phage genome were chemically synthesized by Genscript (Piscataway, NJ) in 14  
387 fragments. The first 7 fragments approximately corresponding to the first half of the T7 genome  
388 were toxic in *E. coli*, and had to be carried on yeast plasmid vector instead of pUC vector. For  
389 assembly, 14 PCR fragments containing compatible *BsaI* junctions were prepared and  
390 subsequently assembled into a complete genome via a 1-step Golden Gate (GG) reaction. After  
391 DNA precipitation, the GG product was used to produce live phages via a cell-free transcription  
392 translation (TXTL) reaction <sup>26</sup>. The full list of constructed phage variants can be found in  
393 Figure S1.

394

### 395 *Golden Gate Assembly*

396 The Golden Gate assembly method has been adapted from Engler et al. and optimized in this  
397 work to achieve high efficiency assembly <sup>27</sup>. Two  $\mu\text{g}$  of purified PCR fragments, in 1:1 molar  
398 ratio, were used in a 20  $\mu\text{L}$  GG reaction. All enzymes were obtained from New England Biolabs  
399 (Ipswich, MA). The reaction was set up with 2  $\mu\text{L}$  T4 DNA Ligase reaction buffer, 0.4  $\mu\text{L}$  high  
400 concentration T4 DNA Ligase (NEB #M0202M), 1.6  $\mu\text{L}$  *BsaI*-HFv2 (NEB #R3733L), made  
401 up to 20  $\mu\text{L}$  with DNA fragments and water. Reactions were carried out on a thermocycler  
402 using the following cycle: (1) 37°C 10min, (2) 37°C 10min, (3) 14°C 6min, (4) Goto (2) for  
403 40X, (5) 14°C 15min, (6) 37°C 15min, (7) 80°C 5min, (8) 10°C hold. To prepare for TXTL  
404 reboot, the GG reaction was precipitated by isopropanol <sup>28</sup> and dissolved in 2  $\mu\text{L}$  water. The  
405 number of cycles can be reduced to 20X for simpler assemblies or when library-efficiency is  
406 not required. Scaling down of the reaction is not recommended as DNA precipitation becomes  
407 more difficult.

408

### 409 *Rebooting of assembled phage genome by cell-free transcription translation (TXTL)*

410 TXTL reaction was done using either myTXTL Sigma 70 Master Mix Kit + GamS or myTXTL  
411 Linear DNA Expression Kit from Arbor Biosciences (Ann Arbor, MI) according to  
412 manufacturer's recommendations. Briefly, each 12  $\mu$ L myTXTL Sigma70 reaction consisted  
413 of 9  $\mu$ L myTXTL mix, 0.8  $\mu$ L 150 $\mu$ M GamS, 0.36  $\mu$ L 10mM dNTP, 0.75  $\mu$ L 40% PEG-8000,  
414 and up to 1.09  $\mu$ L re-dissolved DNA. Condition for myTXTL Linear DNA kit was similar  
415 except that GamS was not needed, and up to 1.89  $\mu$ L re-dissolved DNA could be added.  
416 Reactions were incubated at 29°C for 16 hours and then titered to determine pfu yield. Both  
417 kits resulted in efficient live phage production.

418

#### 419 *Phage genomic DNA purification*

420 Phage genomic DNA were typically prepared from 40 mL of 0.45  $\mu$ m filtered phage lysate.  
421 Bacterial DNA/RNA were digested by adding MgSO<sub>4</sub>, CaCl<sub>2</sub>, DNase I, and RNase A to at 5  
422 mM, 0.5 mM, 5 U/mL, and 5 $\mu$ g/mL final concentration respectively, and incubated at 37 °C  
423 for 90 minutes. Phage particles were concentrated by precipitation and resuspension. Briefly,  
424 solid PEG-8000 and NaCl were added to 10% w/v and 1M respectively followed by overnight  
425 incubation at 4°C. Precipitates were pelleted by centrifugation at 15,000  $\times$ g, 4°C for 20 minutes.  
426 After the complete removal of supernatant, the phage pellet was resuspended in 500  $\mu$ L  
427 resuspension buffer (10 nM Tris pH7.4, 2.5 mM MgSO<sub>4</sub>, 0.5 mM CaCl<sub>2</sub>), and insoluble matter  
428 was removed by centrifugation at 10,000  $\times$ g, 4°C for 3 minutes. Remnant nucleases were  
429 inactivated by adding EDTA and proteinase K to 10 mM and 0.25 mg/mL respectively, and  
430 incubated at 50°C for 15 minutes. DNA were then purified via phenol-chloroform extraction  
431 followed by isopropanol precipitation.

432

#### 433 *Verification of library size by barcode tag analysis*

434 Barcoded phage libraries were generated by GG and rebooted by TXTL. The entire rebooted  
435 phage library was plated on 5  $\times$  100 mm MG1655 lawns, plaques were washed off the plates,  
436 and their genomic DNA were purified from the wash. Using the genomic DNA as template,  
437 two PCR of 10 cycles each were sequentially performed to amplify the tag and to attach NGS  
438 adapters to them. After gel purification, the amplicon library was sequenced on HiSeq using  
439 SE50 chemistry. Raw data output was 1.66 $\times$ 10<sup>8</sup> reads, and the raw data was analyzed using  
440 Galaxy<sup>29</sup>. Detail results of the analysis can be found on Figure S7.

441

#### 442 *Random mutagenesis*

443 Random mutagenesis was performed using GeneMorph II Random Mutagenesis Kit from  
444 Agilent (Santa Clara, CA). The target mutation rate was 5-8 nt changes per gene, and it could  
445 be achieved for smaller amplicons, such as T7 Gp17, using manufacturer's recommendation.  
446 For the larger amplicons, such as T7 Gp11-12 and K11 Gp17, modifications to manufacturer's  
447 protocol were necessary. Briefly, a 1:1 mixture of *Taq* and Mutazyme II DNA polymerase were  
448 used, so as to lower the mutation rate without using excessive template. Clones from the  
449 mutagenized libraries were sequenced by Sanger sequencing to verify the mutation rate. Full  
450 list of engineered mutant phage can be found in Figure S1.

451

#### 452 *Liquid lysis assay*

453 Bacterial strains were grown overnight to saturation in their respective culture media and  
454 condition. Saturated culture were diluted 1:50 and allowed to recover to log-phase for 2 hours.  
455 Log-phase culture were further diluted 1:10 and 200 $\mu$ L of the diluted culture were added to  
456 each well in a transparent flat-bottom 96 well plate. The OD was then recorded at 2 minutes  
457 interval in a plate reader, at culture temperature with intermittent shaking. When growth was  
458 re-established, in approximately 10 minutes, up to 10  $\mu$ L plaque or phage stocks were added  
459 to each well, and the plate was returned to the plate reader to continue the OD recording. For  
460 susceptibility measurement, high titer ( $>10^{10}$  pfu/mL) phage stocks were used to achieve a high  
461 multiplicity of infection (MOI) ( $>5$ ). Burst time was determined using data from the point of  
462 phage addition, and it was defined as the time when the largest change in OD occurred. The  
463 burst timing was found to be independent of MOI, but a MOI at around 0.5 tended to make two  
464 lysis cycles visible, adding to the confidence of lysis timing. List of bacterial strains and their  
465 respective culture condition can be found in Figure S4.

466

#### 467 **AUTHOR CONTRIBUTIONS**

468 JL and HBZ conceptualized the study; JL, HBZ, and YLT performed the experiments; JL,  
469 HMZ, and ELA analyzed the data; JL, HMZ, and ELA wrote and revised the manuscript.

470

#### 471 **CONFLICTS OF INTEREST**

472 None

473

#### 474 **ACKNOWLEDEMENT**

475 Bacteriophage K11, *Klebsiella* sp. 390, and *Yersinia tuberculosis* IP2666 were kind gifts from  
476 Timothy K. Lu, Massachusetts Institute of Technology. This work was supported by HBMS

477 IAF-PP grant (H17/01/a0/0V9) and A\*STAR Visiting Investigator Program (1535j00137 to  
478 H.Z).

479

480 **SUPPORTING INFORMATION**

481 Figure S1. List of phage variants constructed and reported in this work

482 Figure S2. Comparison between T7Syn-TagBs and T7Syn-Tag2Bs

483 Figure S3. Golden Gate efficiency assessment

484 Figure S4. Phage susceptibility testing – liquid lysis

485 Figure S5. Phage susceptibility testing – plating

486 Figure S6. Screening of mutant libraries

487 Figure S7. Tag NGS procedure

488 Table S8. List of fragments used in the domestication of T7 bacteriophage

489 Table S9. List of fragments used in the domestication of K11 Gp11,12,17

490 Table S10. List of PCR primers used in the construction of phage variants

491 Table S11. List of fragments used in the construction of the phage variants listed in Figure S1

492



493 **REFERENCES**

- 494 (1) Review on Antimicrobial Resistance. (2014) Antimicrobial Resistance: Tackling a Crisis  
 495 for the Future Health and Wealth of Nations.
- 496 (2) Sugden, R., Kelly, R., and Davies, S. (2016) Combatting antimicrobial resistance  
 497 globally. *Nat. Microbiol.* *1*, 16187.
- 498 (3) Salmond, G. P. C., and Fineran, P. C. (2015) A century of the phage: past, present and  
 499 future. *Nat. Rev. Microbiol.* *13*, 777–786.
- 500 (4) Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster,  
 501 S., Gilmore, B. F., Hancock, R. E. W., Harper, D., Henderson, I. R., Hilpert, K., Jones, B. V.,  
 502 Kadioglu, A., Knowles, D., Ólafsdóttir, S., Payne, D., Projan, S., Shaunak, S., Silverman, J.,  
 503 Thomas, C. M., Trust, T. J., Warn, P., and Rex, J. H. (2016) Alternatives to antibiotics—a  
 504 pipeline portfolio review. *Lancet Infect. Dis.* *16*, 239–251.
- 505 (5) Kortright, K. E., Chan, B. K., Koff, J. L., and Turner, P. E. (2019) Phage Therapy: A  
 506 Renewed Approach to Combat Antibiotic-Resistant Bacteria. *Cell Host Microbe* *25*, 219–  
 507 232.
- 508 (6) Schmidt, C. (2019) Phage therapy’s latest makeover. *Nat. Biotechnol.* *37*, 581–586.
- 509 (7) Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K.,  
 510 Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., Hatfull, G. F., and  
 511 Spencer, H. (2019) Engineered bacteriophages for treatment of a patient with a disseminated  
 512 drug-resistant *Mycobacterium abscessus*. *Nat. Med.* *25*, 730–733.
- 513 (8) Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L.,  
 514 Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., Segall, A. M., Taplitz, R., Smith, D. M., Kerr,  
 515 K., Kumaraswamy, M., Nizet, V., Lin, L., McCauley, M. D., Strathdee, S. A., Benson, C. A.,  
 516 Pope, R. K., Leroux, B. M., Picel, A. C., Mateczun, A. J., Cilwa, K. E., Regeimbal, J. M.,  
 517 Estrella, L. A., Wolfe, D. M., Henry, M. S., Quinones, J., Salka, S., Bishop-Lilly, K. A.,  
 518 Young, R., and Hamilton, T. (2017) Development and Use of Personalized Bacteriophage-  
 519 Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant *Acinetobacter*  
 520 *baumannii* Infection. *Antimicrob. Agents Chemother.* *61*, e00954-17, /aac/61/10/e00954-  
 521 17.atom.
- 522 (9) Oechslin, F. (2018) Resistance Development to Bacteriophages Occurring during  
 523 Bacteriophage Therapy. *Viruses* *10*, 351.
- 524 (10) Ando, H., Lemire, S., Pires, D. P., and Lu, T. K. (2015) Engineering Modular Viral  
 525 Scaffolds for Targeted Bacterial Population Editing. *Cell Syst.* *1*, 187–196.
- 526 (11) Yosef, I., Goren, M. G., Globus, R., Molshanski-Mor, S., and Qimron, U. (2017)  
 527 Extending the Host Range of Bacteriophage Particles for DNA Transduction. *Mol. Cell* *66*,  
 528 721-728.e3.
- 529 (12) Dunne, M., Rupf, B., Tala, M., Qabrati, X., Ernst, P., Shen, Y., Sumrall, E., Heeb, L.,  
 530 Plückthun, A., Loessner, M. J., and Kilcher, S. (2019) Reprogramming Bacteriophage Host  
 531 Range through Structure-Guided Design of Chimeric Receptor Binding Proteins. *Cell Rep.*  
 532 *29*, 1336-1350.e4.
- 533 (13) Yehl, K., Lemire, S., Yang, A. C., Ando, H., Mimee, M., Torres, M. D. T., de la Fuente-  
 534 Nunez, C., and Lu, T. K. (2019) Engineering Phage Host-Range and Suppressing Bacterial  
 535 Resistance through Phage Tail Fiber Mutagenesis. *Cell* *179*, 459-469.e9.
- 536 (14) Bassalo, M. C., Liu, R., and Gill, R. T. (2016) Directed evolution and synthetic biology  
 537 applications to microbial systems. *Curr. Opin. Biotechnol.* *39*, 126–133.
- 538 (15) Cobb, R. E., Chao, R., and Zhao, H. (2013) Directed evolution: Past, present, and future.  
 539 *AIChE J.* *59*, 1432–1440.
- 540 (16) Molina-Espeja, P., Viña-Gonzalez, J., Gomez-Fernandez, B. J., Martin-Diaz, J., Garcia-  
 541 Ruiz, E., and Alcalde, M. (2016) Beyond the outer limits of nature by directed evolution.  
 542 *Biotechnol. Adv.* *34*, 754–767.

543 (17) Pryor, J. M., Potapov, V., Pokhrel, N., and Lohman, G. J. S. (2020) Rapid 40 kb genome  
544 construction from 52 parts. *bioRxiv* 2020.12.22.424019.

545 (18) Grose, J. H., and Casjens, S. R. (2014) Understanding the enormous diversity of  
546 bacteriophages: The tailed phages that infect the bacterial family Enterobacteriaceae.  
547 *Virology* 468–470, 421–443.

548 (19) Bessler, W., Freund-Mölbart, E., Knüfermann, H., Rudolph, C., Thurow, H., and Stirm,  
549 S. (1973) A bacteriophage-induced depolymerase active on Klebsiella K11 capsular  
550 polysaccharide. *Virology* 56, 134–151.

551 (20) Latka, A., Maciejewska, B., Majkowska-Skrobek, G., Briers, Y., and Drulis-Kawa, Z.  
552 (2017) Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate  
553 barriers during the infection process. *Appl. Microbiol. Biotechnol.* 101, 3103–3119.

554 (21) Deng, W., Burland, V., Plunkett III, G., Boutin, A., Mayhew, G. F., Liss, P., Perna, N.  
555 T., Rose, D. J., Mau, B., Zhou, S., Schwartz, D. C., Fetherston, J. D., Lindler, L. E.,  
556 Brubaker, R. R., Plano, G. V., Straley, S. C., McDonough, K. A., Nilles, M. L., Matson, J. S.,  
557 Blattner, F. R., and Perry, R. D. (2002) Genome Sequence of *Yersinia pestis* KIM. *J.*  
558 *Bacteriol.* 184, 4601–4611.

559 (22) Ibrahim, A., Goebel, B. M., Liesack, W., Griffiths, M., and Stackebrandt, E. (1993) The  
560 phylogeny of the genus *Yersinia* based on 16S rDNA sequences. *FEMS Microbiol. Lett.* 114,  
561 173–177.

562 (23) Saeki, D., Sugiura, S., Kanamori, T., Sato, S., and Ichikawa, S. (2014)  
563 Microcompartmentalized cell-free protein synthesis in semipermeable microcapsules  
564 composed of polyethylenimine-coated alginate. *J. Biosci. Bioeng.* 118, 199–204.

565 (24) Spencer, A. C., Torre, P., and Mansy, S. S. (2013) The Encapsulation of Cell-free  
566 Transcription and Translation Machinery in Vesicles for the Construction of Cellular Mimics.  
567 *J. Vis. Exp.* 51304.

568 (25) Labrie, S. J., Samson, J. E., and Moineau, S. (2010) Bacteriophage resistance  
569 mechanisms. *Nat. Rev. Microbiol.* 8, 317–327.

570 (26) Rustad, M., Eastlund, A., Marshall, R., Jardine, P., and Noireaux, V. (2017) Synthesis of  
571 Infectious Bacteriophages in an *E. coli*-based Cell-free Expression System. *J. Vis. Exp.*  
572 56144.

573 (27) Engler, C., Kandzia, R., and Marillonnet, S. (2008) A One Pot, One Step, Precision  
574 Cloning Method with High Throughput Capability. *PLoS ONE* (El-Shemy, H. A., Ed.) 3,  
575 e3647.

576 (28) Green, M. R., and Sambrook, J. (2017) Precipitation of DNA with Isopropanol. *Cold*  
577 *Spring Harb. Protoc.* 2017, pdb.prot093385.

578 (29) Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Čech, M., Chilton, J.,  
579 Clements, D., Coraor, N., Grüning, B. A., Guerler, A., Hillman-Jackson, J., Hiltmann, S.,  
580 Jalili, V., Rasche, H., Soranzo, N., Goecks, J., Taylor, J., Nekrutenko, A., and Blankenberg,  
581 D. (2018) The Galaxy platform for accessible, reproducible and collaborative biomedical  
582 analyses: 2018 update. *Nucleic Acids Res.* 46, W537–W544.

583

584

585 **Figure legends**

586

587 Figure 1. Complete chemical synthesis and rebooting of Golden Gate compatible T7 phage.  
588 (A) General scheme of assembly, from a user designed genomic sequence to live phage. (B)  
589 Gel electrophoresis of PCR products amplified from phage plaques (Uncut). Syn1 through  
590 Syn8 were amplified from 8 randomly selected T7Syn plaques after assembly and reboot, T7  
591 was amplified from T7wt gDNA, and Ctr1 through Ctr3 were amplified from plaques of  
592 rebooted T7wt gDNA. The PCR products were then digested using *BsaI*, and analyzed on a  
593 separate gel (*BsaI* Cut). (C) Lysates of T7wt and T7Syn titered on BL21 by serial dilutions,  
594 lowest dilution was  $10^{-7}$ . T7wt and T7Syn resulted in similar titers. (D) Burst time comparison  
595 between T7wt and T7Syn. Rate of change of OD is plotted against time, and the burst time is  
596 defined as the time with the largest OD decrease. Data for Syn has been plotted on secondary  
597 axis for clarity. Error bar represents standard deviation of 3 replicates. (E) Liquid culture of  
598 different bacterial strains challenged by T7Syn, T7wt, and T3wt phages. Results shown by  
599 color scale represent the extent of lysis as indicated by a change in OD when compared to a  
600 no-phage control of the same strain. A negative OD change represents lysis, a positive but  
601 reduced OD change represents inhibition, and no difference from no-phage control represents  
602 normal growth, i.e., complete resistance. Partial results (36 of 47 strains tested) shown here,  
603 the full list can be found in Figure S4. Image Credit: Illustration of T7 bacteriophage has been  
604 adapted from [https://cronodon.com/BioTech/Virus\\_Tech\\_2.html](https://cronodon.com/BioTech/Virus_Tech_2.html) with permission.

605

606 Figure 2. Functionalization and modification of T7Syn genome. (A) Schematic of T7Syn  
607 modifications used for generating Gp17 random mutagenesis and Gp17 random tag libraries.  
608 (B) Confirmation of *BsaI* site insertions. Gel electrophoresis of *BsaI* digested gDNA purified  
609 from modified phages. Molecular marker was the NEB 1kb extended DNA ladder, the top band  
610 is 48.5 kb and the dark band is 3 kb. a-e are the expected bands generated by *BsaI* sites flanking  
611 Gp11-12, in pink, or Gp17, in orange. (C) Burst time evaluation of the T7Syn variants. Rate of  
612 change of OD is plotted against time, and the burst time is defined as the time with the largest  
613 OD decrease. Error bar represents standard deviation of 3 replicates.


614

615 Figure 3. Evolving new host specificity. (A) Titering of T7Syn-17T3 lysate on *E. coli* BL21  
616 (B strain) and MG1655 (K12 strain). The efficiency of plating was  $< 10^{-7}$ . (B) Titering of  
617 plaque stocks on MG1655. T3m showed 4 randomly selected plaques of a rebooted T7Syn-  
618 17T3 tail fiber random mutagenesis phage library, whereas T3c showed 4 randomly selected

619 plaques of a rebooted negative control with a wild-type T3 tail fiber swapped in. (C) Dilution  
620 of T7wt, T7Syn, and T3 phages titered on YE. Zones of inhibition is visible at high T7 and Syn  
621 concentration, but no individual plaque can be seen. (D) Plating of phages on YE for plaque  
622 isolation. Top: at least  $3 \times 10^5$  pfu of Gp17 random mutagenesis phage library, many small but  
623 clearly visible plaques can be seen. Bottom:  $\sim 1 \times 10^6$  pfu of T7Syn phage, no plaque can be  
624 observed. (E) Titers of 4 randomly selected plaques isolated from Gp17 random mutagenesis  
625 phage library plated on YE. Top: plaque stock showed varying degree of activity against YE.  
626 Middle: plaque stocks retained full activity towards K12 strain. Bottom: plaque stocks were  
627 fully active against *Yersinia pseudotuberculosis* IP2666. (F) YE burst time comparison  
628 between the best performing first and second round variants. Rate of change of OD is plotted  
629 against time, and the burst time is defined as the time with the largest OD decrease. Error bar  
630 represents standard deviation of 3 replicates. Two separate bursts of lysis were clearly visible  
631 for 17m5 (1<sup>st</sup> round mutant), 12m1 (2<sup>nd</sup> round Gp11-12 mutant) and 5m7 (2<sup>nd</sup> round Gp17  
632 mutant), the 2<sup>nd</sup> round mutant being slightly faster than the 1<sup>st</sup> round mutant. No lytic activity  
633 towards YE was observed for unmutated T7wt phage. (G) and (H) Lysis of BL21 by the Gp17  
634 mutants and their parent phages. OD is plotted against time. Error bar represents standard  
635 deviation of 3 replicates. (G) All variants and their parents completely lysed BL21 within the  
636 first hour. T7Syn-17m5 was more active than the parent phage, whereas T7Syn-5m7 was less  
637 active than parent phage. (H) Resistance against the parent phages led to an increase in OD by  
638 the 12<sup>th</sup> hour. The rise of resistance was suppressed by both T7Syn-17m5 and T7Syn-5m7.


639  
640 Figure 4. Mutagenesis of T7-K11 hybrids. (A) Schematic of T7Syn variants used for generating  
641 the T7-K11 hybrids. T7Syn-K1112K17 had its Gp11, Gp12, and Gp17 replaced by the  
642 homologous genes from K11 phage, *BsaI*-inserted variants were also created to allow  
643 mutagenesis, T7Syn-TK17 had its Gp17 C-terminus replaced by that from K11 phage. (B)  
644 Titering of two completed TXTL reactions on K390. T7Syn-K1112K17, reassembled using a  
645 5-fragment Golden Gate reaction, resulted in a titer of  $\sim 10^3$  per  $\mu\text{L}$ . T7Syn-TK17, reassembled  
646 from a direct Golden Gate swap-in, resulted in a titer of  $\sim 10^6$  per  $\mu\text{L}$ . These yields are typical  
647 for their respective assembly complexity. (C) and (D) Lysis of K390 by T7-K11 hybrid variants  
648 and their parent phages. OD is plotted against time. Error bar represents standard deviation of  
649 3 replicates. T7Syn-KmL2 is an improved mutant isolated from a Gp11,12,17 random  
650 mutagenesis library plated on K390 in LB. (C) Lysis curve of K390 in NB. All variants could  
651 lyse K390 in NB. (D) Lysis curve of K390 in LB. Although the wild type K11 phage can lyse

- 652 K390 efficiently in LB, K390 in LB is much more resistant to lysis by the T7-K11 hybrids.
- 653 KmL2 showed marked improvement over its T7-K11 hybrid parents.



654  
 655  
 656  
 657


Figure 1



658

659

660 Figure 2




661

662 Figure 3

663






664

665

666 Figure 4

667

668



669

670 Table-of-Content Graphic